Strategy
← Отчётные звонки
01
02
03
04 05 06
Тон
A1 A2 A3
INCY
FY2026 Q2
Повышен
Отчётный звонок Incyte Corporation
Вывод Buzzberg
Company no longer dependent on single asset, multiple growth drivers
Incyte reported strong Q2 2026 results with total product sales up 40% YoY, largely driven by one-time gains from a CMS settlement and continued core growth. Management raised full-year 2026 revenue guidance, citing strength across the portfolio and pipeline progress, and highlighted new launches and data readouts ahead. Total Q2 2026 product sales were $1.49B, up 40% YoY, with a $246M one-time non-cash benefit from the CMS settlement.
Вывод Buzzberg Company no longer dependent on single asset, multiple growth drivers Incyte reported strong Q2 2026 results with total product sales up 40% YoY, largely driven by one-time gains from a CMS settlement and continued core growth. Management raised full-year 2026 revenue guidance, citing strength across the portfolio and pipeline progress, and highlighted new launches and data readouts ahead. Total Q2 2026 product sales were $1.49B, up 40% YoY, with a $246M one-time non-cash benefit from the CMS settlement. Читать полный анализСвернуть анализ
Incyte reported strong Q2 2026 results with total product sales up 40% YoY, largely driven by one-time gains from a CMS settlement and continued core growth. Management raised full-year 2026 revenue guidance, citing strength across the portfolio and pipeline progress, and highlighted new launches and data readouts ahead. Total Q2 2026 product sales were $1.49B, up 40% YoY, with a $246M one-time non-cash benefit from the CMS settlement.
- Incyte raised its full-year 2026 total net sales guidance to $5.13-$5.26B.
- The core business (ex-Jakafi) grew 44% YoY, driven by Opzelura, Niktimbo, Monjuvi, and Zynyz.
- Management emphasized a transition away from dependence on a single asset (Jakafi) toward a multi-product, late-stage pipeline.
JAKAFI Выручка$0.817BФакт
OPSALURA Выручка$0.45BФакт
Выручка$1.674B+32% к/к
EPS$3.09Факт
6 подтверждённых тезисов
Что важно сейчас
Самые значимые изменения по итогам звонка.
Margins
Opsalura CMS settlement improves gross-to-net profile
Pipeline
Latarsabart could be a 'Hemlibra-like' opportunity
Показать ещё 3 тезиса
Pipeline
989 phase 3 in MF to start after FDA discussions
Pipeline
ESMO data expected to de-risk 734 in pancreatic cancer
Commercial
Jackify XR formulary coverage on track to 50-70%
Отчётный период
Фактические результаты
| Показатель | Факт | Изменение |
|---|---|---|
| JAKAFI Выручка | $0.817B | Факт |
| OPSALURA Выручка | $0.45B | Факт |
| Выручка | $1.674B | +32% к/к |
| EPS | $3.09 | Факт |
| Операционная маржа | 41.69% | Факт |
| Свободный денежный поток | $0.4952B | +38% к/к |
Прогнозные данные
Прогноз компании
| Показатель | Период | Диапазон | Середина | Статус |
|---|---|---|---|---|
| Операционная маржа | FY2026 | $4.915B–$4.995B | $4.955B | Повышен |
| Операционная маржаTOTAL_NON_GAAP | FY2026 | $4.625B–$4.695B | $4.66B | Повышен |
| Выручка | FY2026 | $5.13B–$5.26B | $5.195B | Повышен |
| ВыручкаOPSALURA | FY2026 | $1.05B–$1.1B | $1.075B | Повышен |
| ВыручкаHEMATOLOGY_ONCOLOGY | FY2026 | $0.86B–$0.89B | $0.875B | Повышен |
AI, капзатраты и спрос
Оценка менеджмента
Confident
Management expressed strong confidence in the company's transition, execution, and pipeline progress, repeatedly emphasizing tangible achievements and a positive outlook.
все упомянутые компании ниже: 5
Компаниис момента звонка
Партнёры
Партнёры
Suki
Novartis's settlement with Incyte reduced Incyte's expense base in the prior year, indicating a financial relationship between the companies.
Доказательства
“The year-over-year increase reflects a lower expense base in the second quarter of 2025, resulting from the Novartis settlement of $242 million.”
Партнёры
Pablo
Syndax is running the Niktimbo IPF study; its data readout will be a key catalyst for a potential opt-in decision by Incyte.
Доказательства
“The disclosure of the data, since they're conducting the study, will be done by Syndex.”
Партнёры
Pablo
Collaborating with Halozyme to optimize the subcutaneous formulation of 9A9 using their enhanced delivery technology adds optionality and could improve patient experience for the drug.
Доказательства
“We recently entered a global collaboration and license agreement with Halozyme to evaluate the subcutaneous formulation of 9A9 using enhanced technology.”
Партнёры
Pablo
Incyte has a collaboration with Prelude for JAK2V617F assets, but owns the decision on whether to opt in based on data coming from Prelude.
Доказательства
“On the Prelude Agreement, obviously those programs are managed by Prelude.”
Цепочка поставок
Цепочка поставок
Bill
Niktimbo is growing by gaining market share in third-line plus myelofibrosis, but the recent data from other companies like Gilead's momelotinib could heighten competition in this setting. — With a third of the market, Incyte faces direct competition from Gilead's momelotinib and possibly others; maintaining this share is key to the heme-onc portfolio's growth.
Доказательства
“We currently hold approximately one third of the third line plus market.”
Внешние сигналы
Альфа цепочки поставок · 3с момента звонка
Incyte's 989 MPN program may use a differentiated regulatory path with the FDA that could include novel efficacy endpoints like hemoglobin improvement, potentially setting a new precedent for MPN trials.
Доказательства
“We thought and still think it's important to have a constructive dialogue with the FDA to see how we can incorporate some of these endpoints that reflect the benefit patients receive from 9A9.”
Incyte discontinuing 058 highlights increased risk in the JAK2V617F inhibitor space, but they signal a next-gen program with better data is advancing toward the clinic.
Доказательства
“We decided to discontinue development 058, our lead asset in our JAK2V617F targeted pipeline, and are no longer expecting to report data later this year. ... The next generation programs have moved along very, very well.”
Niktimbo is growing by gaining market share in third-line plus myelofibrosis, but the recent data from other companies like Gilead's momelotinib could heighten competition in this setting.
Методология и полнота
Анализ основан только на заявлениях менеджмента. Показаны все подтверждённые упоминания компаний: 5. Фактические результаты и прогнозы разделены. Публичные доказательства ограничены восемью короткими атрибутированными цитатами. AI-анализ может быть неполным или ошибочным — проверяйте важные утверждения по первоисточнику.